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(persistent) asthma compared montelukast 5 mg
(Singulair) once a day plus inhaled budesonide
200 µg (Pulmicort) twice a day with placebo plus
budesonide (Rhinocort). Each study period lasted
only 4 weeks, starting after a 4-week run-in 
period. Montelukast modestly improved asthma
control over placebo. Compared with the placebo
period, montelukast decreased the average use of
beta-agonists by 1 puff per day. Asthma exacerba-
tion days decreased by about 1 per month during
montelukast treatment. The effects of mon-
telukast and placebo on forced expiratory volume
in 1 second (FEV1), quality of life, and adverse
events did not differ significantly.3
One randomized, open-label crossover study of
124 children with “mild” asthma found that mon-
telukast provided equivalent control and superior
patient and parent satisfaction when compared
with inhaled corticosteroids. Outcomes assessed
were FEV1, school and work loss, medical
resource utilization, safety, and patient and parent
satisfaction. Children entering this study were self-
selected to extend participation from a previous
larger study that did not meet Cochrane quality 
criteria for inclusion in meta-analysis. The authors
acknowledge the potential for selection bias.4
A randomized, double-blind, placebo-controlled
study of 338 patients aged 12 years to adult com-
pared zafirlukast (Accolate) with fluticasone pro-
pionate (Flovent) for control of persistent asthma.
This study concluded that fluticasone was superior
for all clinical outcomes measured including symp-
tom scores, albuterol use, nighttime awakenings
pulmonary function, and number of exacerbations
requiring oral corticosteroids. Pooling of adult and
adolescent cases in this study limits generalized
application of these results to pediatric practice.
5
■ RECOMMENDATIONS FROM OTHERS
The National Asthma Education and Prevention
Program6 and the Global Initiative for Asthma7
guidelines conclude that inhaled corticosteroid,
at the lowest effective dose, is the preferred
therapy for children of all ages with persistent
asthma whether mild, moderate, or severe.
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■ EVIDENCE-BASED ANSWER
Evidence on the use of leukotriene inhibitors in
children is insufficient to permit conclusions
regarding efficacy. Given the proven efficacy of
inhaled corticosteroids in asthma management,
leukotriene inhibitors should not replace inhaled
corticosteroids for maintenance of asthma in 
children (strength of recommendation: B). 
Current guidelines that list leukotriene
inhibitors as a potential addition or alternative to
corticosteroid therapy in children with asthma
appear to be based on scant studies and extrapo-
lation from adult research. 
■ EVIDENCE SUMMARY
Asthma is characterized by inflammation of the
bronchial airways. Leukotrienes are potent media-
tors of inflammation and are believed to contribute
significantly to the inflammatory pathophysiology
of asthma. Leukotriene inhibitors interfere with
leukotriene production or leukotriene receptors
and thus inhibit inflammation.1
Leukotriene inhibitors are administered orally,
a significant advantage over inhalation in the pedi-
atric population. For children, the theoretical cor-
ticosteroid-sparing effect of leukotriene inhibitors
is appealing but has not been demonstrated. 
In January 2002, Cochrane reviewers identified
3 studies of leukotriene inhibitor use in children
that met their quality criteria for meta-analysis.
Unfortunately, recent changes in asthma classifi-
cation terminology make it difficult to precisely
translate past studies into current practice. Based
on these studies, the Cochrane reviewers conclud-
ed there is insufficient evidence to support the use
of leukotriene inhibitors in children as monother-
apy or as an addition to corticosteroids.1,2
One randomized, double-blind crossover study
of 279 children with corticosteroid-dependent
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Both guidelines list leukotriene inhibitors as
a potential adjunct to corticosteroids for moder-
ate persistent asthma, as an alternative to cor-
ticosteroids plus long-acting beta2-agonist. The
guidelines also list leukotriene inhibitors as an
alternative treatment to inhaled corticosteroids
for mild persistent asthma in patients aged >5
years. Montelukast (Singulair) is approved for
use in children aged >12 months, zafirlukast
(Accolate) is approved for children aged >5
years, and zileuton (Zyflo) is approved only for
children aged >12 years.
Nancy E. Morden, MD, Department of Family Medicine,
University of Washington, Seattle; Leilani St. Anna,
MLIS, AHIP, University of Washington Health Sciences
Library, Seattle
■ CLINICAL COMMENTARY
An inhaled corticosteroid controller 
should be the first step
Until evidence supports a different conclu-
sion, I think we should continue to follow
current national and global guidelines. The
most important concept in both is that once a
child is diagnosed with persistent asthma,
starting an inhaled corticosteroid controller
should be the first step. 
Leukotriene inhibitors should be considered
as second or third choice as a controller. The
main indications for using a leukotriene
inhibitor are aspirin-sensitive, exercise-
induced, and nocturnal asthma. I would use a
leukotriene inhibitor as a controller only if a
patient could not comply with inhaled corti-
costeroids.
Lawrence S. Slotnick, MD, Moses Cone Health
System, Greensboro, NC
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Which blood tests are 
most helpful in evaluating 
pelvic inflammatory disease?
■ EVIDENCE-BASED ANSWER 
No individual or combination of blood tests can reli-
ably diagnose pelvic inflammatory disease (PID)
(strength of recommendation [SOR]: A, meta-
analysis). The combination of white blood cell
count, C-reactive protein (CRP), erythrocyte sedi-
mentation rate (ESR), and vaginal white blood cells
can reliably exclude PID if results for all 4 tests are
normal (sensitivity=100%) (SOR: B, cohort study,
reference standard not uniformly applied). 
The combination of CRP and ESR is helpful in
excluding PID (sensitivity=91%) and may be
especially useful in distinguishing mild from com-
plicated cases (SOR: B, small cohort study).
Individual tests do not appear to significantly
improve diagnostic accuracy, although the CRP
and ESR are somewhat useful to rule out PID
(SOR: B, small cohort study).
■ EVIDENCE SUMMARY
Because of the significant inflammatory sequelae
of PID, it is the standard of care to treat women
with suggestive signs and symptoms. Clinical
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